Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation.
10.3350/kjhep.2008.14.4.519
- Author:
Byung Kook KIM
1
;
So Young KWON
;
Soon Young KO
;
Won Hyeok CHOE
;
Chang Hong LEE
;
He Seong HAN
;
Seong Hwan CHANG
Author Information
1. Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. sykwonmd@hotmail.com
- Publication Type:Case Report ; English Abstract
- Keywords:
Hepatitis C;
Liver Transplantation;
Cholestasis;
Fibrosis
- MeSH:
Antiviral Agents/*administration & dosage;
Cholestasis, Intrahepatic/*diagnosis/pathology;
Combined Modality Therapy;
Hepacivirus/drug effects;
Hepatitis C, Chronic/diagnosis/*drug therapy/pathology;
Humans;
Interferon Alfa-2a/*administration & dosage;
*Liver Transplantation;
Male;
Middle Aged;
Polyethylene Glycols/*administration & dosage;
RNA, Viral/analysis;
Recurrence;
Ribavirin/*administration & dosage;
Tomography, X-Ray Computed
- From:The Korean Journal of Hepatology
2008;14(4):519-524
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon alpha-2a and ribavirin.
